For Year 2025-26, Glenmark Pharmaceuticals reports the following shareholding: Total Promoters at 46.65%, Mutual Fund at 17.86%, Insurance at 1.03%, Foreign Institutional Investors at 19.2%, Domestic Institutional Investors at 1.24%, and Retail at 14.02%. This breakdown provides a quick snapshot of ownership distribution for Glenmark Pharmaceuticals in 2025-26.